Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis

IF 4.9 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity Pub Date : 2026-09-02 Epub Date: 2026-06-14 DOI:10.1002/oby.70231

Regina Castaneda, Dima Bechenati, Rene de J. Rivera Gutierrez, Maria A. Espinosa, Jose Villamarin, Elif Tama, Nancy Safwan, Sima Fansa, Alfredo Verastegui, Allyson W. McNally, Jesse L. Meek, Kristin C. Cole, Stacey J. Winham, Tamim I. Rajjo, Andres Acosta, Stephanie S. Faubion, Chrisandra L. Shufelt, Maria D. Hurtado Andrade

{"title":"Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis","authors":"Regina Castaneda, Dima Bechenati, Rene de J. Rivera Gutierrez, Maria A. Espinosa, Jose Villamarin, Elif Tama, Nancy Safwan, Sima Fansa, Alfredo Verastegui, Allyson W. McNally, Jesse L. Meek, Kristin C. Cole, Stacey J. Winham, Tamim I. Rajjo, Andres Acosta, Stephanie S. Faubion, Chrisandra L. Shufelt, Maria D. Hurtado Andrade","doi":"10.1002/oby.70231","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study assessed the impact of sex and age on weight loss outcomes in patients receiving tirzepatide in real-world clinical practice.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a retrospective cohort study of adults with overweight or obesity who initiated tirzepatide at Mayo Clinic between June 2022 and May 2024 and completed ≥ 12 months of continuous therapy. Primary outcome was total body weight loss percentage (TBWL%) at 15 months, stratified by sex and age groups (≤ 45, 46–59, ≥ 60 years).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 1039 patients (57% women; mean age 56 ± 11 years), women achieved significantly greater TBWL% than men after 15 months of treatment (15.1% vs. 10.7%, <i>p</i> < 0.001). Patients aged ≤ 45 years had greater weight loss than those ≥ 60 years (15.1% vs. 12.3%, <i>p</i> = 0.024). In multivariable analyses, greater weight loss was independently associated with female sex, absence of type 2 diabetes, no prior obesity medication use, no concomitant weight gain-promoting medications, and higher tirzepatide dosage. Age was not an independent predictor.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Sex, but not age, predicted weight loss with tirzepatide among individuals using the medication continuously for ≥ 12 months. These findings underscore the importance of incorporating sex-specific considerations into personalized obesity treatment strategies.</p>\n </section>\n </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"132-145"},"PeriodicalIF":4.9000,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.70231","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study assessed the impact of sex and age on weight loss outcomes in patients receiving tirzepatide in real-world clinical practice.

Methods

We conducted a retrospective cohort study of adults with overweight or obesity who initiated tirzepatide at Mayo Clinic between June 2022 and May 2024 and completed ≥ 12 months of continuous therapy. Primary outcome was total body weight loss percentage (TBWL%) at 15 months, stratified by sex and age groups (≤ 45, 46–59, ≥ 60 years).

Results

Among 1039 patients (57% women; mean age 56 ± 11 years), women achieved significantly greater TBWL% than men after 15 months of treatment (15.1% vs. 10.7%, p < 0.001). Patients aged ≤ 45 years had greater weight loss than those ≥ 60 years (15.1% vs. 12.3%, p = 0.024). In multivariable analyses, greater weight loss was independently associated with female sex, absence of type 2 diabetes, no prior obesity medication use, no concomitant weight gain-promoting medications, and higher tirzepatide dosage. Age was not an independent predictor.

Conclusions

Sex, but not age, predicted weight loss with tirzepatide among individuals using the medication continuously for ≥ 12 months. These findings underscore the importance of incorporating sex-specific considerations into personalized obesity treatment strategies.

查看原文本刊更多论文

性别，而不是年龄，预测替西肽的减肥结果：一项回顾性分析。

目的：本研究评估了在现实世界的临床实践中，性别和年龄对接受替西帕肽治疗的患者减肥结果的影响。方法：我们对2022年6月至2024年5月期间在梅奥诊所开始使用替西帕肽并完成≥12个月连续治疗的超重或肥胖成人进行了回顾性队列研究。主要终点是15个月时的总体重减轻率（TBWL%），按性别和年龄组分层（≤45岁，46-59岁，≥60岁）。结果：在1039例患者中（57%为女性，平均年龄56±11岁），在治疗15个月后，女性的TBWL显著高于男性（15.1% vs. 10.7%, p）。结论：性别，而不是年龄，可以预测连续用药≥12个月的替西肽患者的体重减轻。这些发现强调了将性别特异性因素纳入个性化肥胖治疗策略的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity 医学-内分泌学与代谢

CiteScore

11.70

自引率

1.40%

发文量

261

审稿时长

2-4 weeks

期刊介绍： Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.